Hansa Biopharma's market value is the price at which a share of Hansa Biopharma trades on a public exchange. It measures the collective expectations of Hansa Biopharma AB investors about its performance. Hansa Biopharma is trading at 2.91 as of the 27th of December 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 2.91. With this module, you can estimate the performance of a buy and hold strategy of Hansa Biopharma AB and determine expected loss or profit from investing in Hansa Biopharma over a given investment horizon. Check out Hansa Biopharma Correlation, Hansa Biopharma Volatility and Hansa Biopharma Alpha and Beta module to complement your research on Hansa Biopharma.
Please note, there is a significant difference between Hansa Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hansa Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hansa Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Hansa Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Hansa Biopharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Hansa Biopharma.
0.00
11/27/2025
No Change 0.00
0.0
In 31 days
12/27/2025
0.00
If you would invest 0.00 in Hansa Biopharma on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Hansa Biopharma AB or generate 0.0% return on investment in Hansa Biopharma over 30 days. Hansa Biopharma is related to or competes with Silence Therapeutics, Transgene, Cellectis, Santhera Pharmaceuticals, Immutep, Genfit SA, and Frontage Holdings. Hansa Biopharma AB , a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare... More
Hansa Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Hansa Biopharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Hansa Biopharma AB upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hansa Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Hansa Biopharma's standard deviation. In reality, there are many statistical measures that can use Hansa Biopharma historical prices to predict the future Hansa Biopharma's volatility.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Hansa Biopharma. Your research has to be compared to or analyzed against Hansa Biopharma's peers to derive any actionable benefits. When done correctly, Hansa Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Hansa Biopharma AB.
Hansa Biopharma AB Backtested Returns
Hansa Biopharma appears to be dangerous, given 3 months investment horizon. Hansa Biopharma AB holds Efficiency (Sharpe) Ratio of 0.0314, which attests that the entity had a 0.0314 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Hansa Biopharma AB, which you can use to evaluate the volatility of the firm. Please utilize Hansa Biopharma's Risk Adjusted Performance of 0.0308, standard deviation of 7.94, and Market Risk Adjusted Performance of 4.39 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Hansa Biopharma holds a performance score of 2. The company retains a Market Volatility (i.e., Beta) of 0.0538, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Hansa Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Hansa Biopharma is expected to be smaller as well. Please check Hansa Biopharma's variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to make a quick decision on whether Hansa Biopharma's current trending patterns will revert.
Auto-correlation
0.00
No correlation between past and present
Hansa Biopharma AB has no correlation between past and present. Overlapping area represents the amount of predictability between Hansa Biopharma time series from 27th of November 2025 to 12th of December 2025 and 12th of December 2025 to 27th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Hansa Biopharma AB price movement. The serial correlation of 0.0 indicates that just 0.0% of current Hansa Biopharma price fluctuation can be explain by its past prices.
Correlation Coefficient
0.0
Spearman Rank Test
1.0
Residual Average
0.0
Price Variance
0.0
Hansa Biopharma AB lagged returns against current returns
Autocorrelation, which is Hansa Biopharma pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Hansa Biopharma's pink sheet expected returns. We can calculate the autocorrelation of Hansa Biopharma returns to help us make a trade decision. For example, suppose you find that Hansa Biopharma has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values
Timeline
Hansa Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Hansa Biopharma pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Hansa Biopharma pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Hansa Biopharma pink sheet over time.
Current vs Lagged Prices
Timeline
Hansa Biopharma Lagged Returns
When evaluating Hansa Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Hansa Biopharma pink sheet have on its future price. Hansa Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Hansa Biopharma autocorrelation shows the relationship between Hansa Biopharma pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Hansa Biopharma AB.
Other Information on Investing in Hansa Pink Sheet
Hansa Biopharma financial ratios help investors to determine whether Hansa Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hansa with respect to the benefits of owning Hansa Biopharma security.